26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cisplatin (CDDP) resistance is a major clinical problem associated with poor prognosis in gastric cancer (GC) patients. In this study, we performed integrated analysis of TCGA data from microRNAs (miRNAs) expression matrix of GC patients who received CDDP-based chemotherapy with GEO dataset which contains differential miRNAs expression profiles in CDDP-resistant and -sensitive cell lines. We identified miR-148a-3p downregulation as a key step involved in CDDP resistance. Using a cohort consisting 105 GC patients who received CDDP-based therapy, we found that miR-148a-3p downregulation was associated with a decrease in patients’ disease-free survival (DFS, P=0.0077). A series of experiment data demonstrated that: 1) miR-148a-3p was downregulated in CDDP-resistant GC cell lines; 2) miR-148a-3p reconstitution sensitized CDDP-resistant cells to CDDP treatment through promoting mitochondrial fission and decreasing AKAP1 expression level; 3) AKAP1 played a novel role in CDDP resistance by inhibiting P53-mediated DRP1 dephosphorylation; 4) miR-148a-3p reconstitution in CDDP-resistant cells inhibits the cyto-protective autophagy by suppressing RAB12 expression and mTOR1 activation. Taken together, our study demonstrates that miR-148a-3p could be a promising prognostic marker or therapeutic candidate for overcoming CDDP resistance in GC.

          Related collections

          Author and article information

          Journal
          7600053
          2780
          Cancer Lett
          Cancer Lett.
          Cancer letters
          0304-3835
          1872-7980
          20 October 2017
          28 September 2017
          01 December 2017
          01 December 2018
          : 410
          : 212-227
          Affiliations
          [1 ]Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu province, China
          [2 ]Department of Surgery and Cancer Biology, Vanderbilt University Medical Center, Nashville, 37232, Tennessee, USA
          [3 ]Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu province, China
          [4 ]Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, 37232, Tennessee, USA
          Author notes
          [* ]Correspondence to: Zekuan Xu, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou road, Nanjing, 210029, Jiangsu province, China. xuzekuan@ 123456njmu.edu.cn ; Wael El-Rifai, Department of Surgery and Cancer Biology, Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville, 37232, Tennessee, USA. wael.el-rifai@ 123456vanderbilt.edu
          [5]

          These authors contributed equally to this work.

          Article
          PMC5675767 PMC5675767 5675767 nihpa912366
          10.1016/j.canlet.2017.09.035
          5675767
          28965855
          2830b08e-de55-48fc-afde-f814622fd3f7
          History
          Categories
          Article

          Cisplatin sensitivity,RAB12,AKAP1,miR-148a-3p,Gastric cancer

          Comments

          Comment on this article